Profile of:

Ennio Lubrano

Ennio Lubrano is Full Professor of Rheumatology at the Department of Medicine and Health Sciences “Vincenzo Tiberio” and Head of the Internal Medicine and Rheumatology Unit, both at the University of Molise in Campobasso, Italy. He received his medical degree from University of Naples “Federico II” (Naples, Italy) and completed his residency in rheumatology and earned his at the Sapienza - University of Rome (Rome, Italy) and earned his PhD in Rheumatology at University of Naples "Federico II" (Naples, Italy). He is Steering Committee member of GRAPPA Group and executive of the Italian Society for Rheumatology (SIR) Prof. Lubrano is a leading researcher in emerging therapies and outcomes measures in spondyloarthritis. He has published more than 190 articles and abstracts in peer-reviewed journals including Annals of the Rheumatic Diseases, The Lancet Rheumatolgy,The Journal of Rheumatology, Journal of Psoriasis and Psoriatic Arthritis, Rheumatology and Therapy, and Clinical and Experimental Rheumatology. He is the national coordinator of the CLASSIC study and Team Leader of Axial Subset of the GRAPPA treatment recommendation.

Full name: Ennio Lubrano

Current country: Italy

Membership level: Full

Type of membership: Member

Number of publications: 63

The Conundrum of Psoriatic Arthritis: a Pathogenetic and Clinical Pattern at the Midpoint of Autoinflammation and Autoimmunity (2022)

Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients (2021)

Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab (2021)

Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk (2021)

Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician (2021)

MRI Assessment of Extra-axial Findings at Pelvic Sites in a Group of Axial-SpA Patients (2021)

The “Climb” Towards Minimal Disease Activity in Psoriatic Arthritis (2021)

Corticosteroid injection treatment for dactylitis in psoriatic arthritis (2021)

A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action (2021)

What influences patients’ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study (2021)

New Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review (2021)

Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study (2021)

To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis (2021)

Assessment of Widespread and Extraarticular Pain in Psoriatic Arthritis: A Case-control Study (2021)

Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study (2021)

The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status? (2021)

Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative (2020)

ARS-CoV-2 IgM False- Positivity in a Psoriatic Arthritis Patient Seropositive for Rheumatoid Factor and ACPA: An Interference of Immune Response? (2020)

Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial (2020)

Multimorbidity and comorbidity in psoriatic arthritis – a perspective (2020)

Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment (2020)

Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study (2020)

Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices (2020)

Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real- Life Study (2020)

Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross-sectional, multi-country, observational study (2020)

The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis (2020)

Residual Disease Activity and Associated Factors in Psoriatic Arthritis (2020)

Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries (2020)

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study (2019)

Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome? (2019)

TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis (2019)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients (2019)

New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review (2019)

Assessment of bone morphogenic protein 2 and interleukin-17A in patients with axial spondyloarthritis and their potential role in the new bone formation: a cross-sectional study (2019)

Occult axial involvement in patients with psoriatic arthritis mutilans: a case report (2019)

The Assessment of Disease Activity in Psoriatic Arthritis: MDA, VLDA, DAPSA, or Something Else? (2019)

Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting (2019)

Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement (2019)

Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis (2019)

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries (2019)

Role of comorbidities in spondyloarthritis including psoriatic arthritis (2019)

What Should Be the Primary Target of “Treat to Target” in Psoriatic Arthritis? (2019)

Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis (2019)

Clinical implications of peripheral new bone formation in psoriatic arthritis: a literature-based review (2019)

Abatacept for the treatment of psoriatic arthritis (2018)

Physician’s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study (2018)

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study (2018)

Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease (2018)

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis (2018)

From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications (2018)

Consensus on the management of patients with psoriatic arthritis in a dermatology setting (2018)

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis (2018)

Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature (2018)

Unmet Needs in Axial Spondyloarthritis (2018)

Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology (2017)

Psoriatic arthritis: is it time to treat-to-target or target to treat? (2017)

Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts (2017)

Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate (2017)

Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort (2017)

Mesenchimal stem cells: a possible role in the pathogenesis and treatment of spondyloarthritis (2017)

The role of IL-17 in the treatment of psoriatic arthritis (2017)

Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients (2017)

Secukinumab for ankylosing spondylitis and psoriatic arthritis (2016)